MedTrace Logo

ND-12 Combined With H-6 for Adult Chronic Inflammatory Diarrhea

NCT07767370 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2026-08-17

No results posted yet for this study

Summary

This is a randomized controlled trial to explore the efficacy and safety of ND-12 combined with H-6 for patients with chronic inflammatory diarrhea

Conditions

  • Diarrhea Chronic
  • UC - Ulcerative Colitis

Interventions

DRUG

mesalazine

Take 4 melesalazine capsules each time, 3 times a day. Continue for 14 days.

DRUG

ND-12

Take 1 ND-12 capsule and 3 blank capsules each time, 3 times a day. Continue for 14 days

DRUG

ND-12/H-6

Take 1 ND-12 capsule and 3 H-6 capsules each time, 3 times a day. Continue for 14 days

Sponsors & Collaborators

  • Neurodawn Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • The Second Hospital of Nanjing Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-20
Primary Completion
2028-08-31
Completion
2028-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07767370 on ClinicalTrials.gov